Shanghai Pharma details stock option exercise, ownership shift

Shanghai Pharmaceuticals Holding Co., Ltd. announced the restricted exercise period for the third tranche of reserved stock options under its 2019 A-share incentive plan. The exercise period is from February 8, 2025, to February 7, 2026, with a specific restriction period for all eligible participants from October 1 to October 30, 2025. The company will facilitate the necessary procedures.

Concurrently, Shanghai Pharmaceuticals disclosed changes in its indirect ownership structure. Shanghai SUSHI Changsanjiao Ecological Development Co., Ltd. transferred its 40% equity stake in Shanghai Pharmaceutical (Group) Co., Ltd. (SPGC) to Shanghai SUSHI (Group) Co., Ltd. for a total consideration of RMB 672,151.48万元. Prior to this transfer, Shanghai SUSHI Changsanjiao indirectly held 286,606,415.6 A-shares of Shanghai Pharmaceuticals, representing 7.729% of its share capital. Following the transaction, Shanghai SUSHI Changsanjiao will no longer hold any equity in SPGC, eliminating its indirect stake in Shanghai Pharmaceuticals.

In related news, Mr. Mao Jiayi resigned as vice president of Shanghai Pharmaceuticals, effective September 25, 2025, due to a work relocation. He will continue to serve as chairman of Shanghai S.P. Sine Pharmaceutical Laboratories Co., Ltd. and Shanghai China-Western Three-Dimensional Pharmaceutical Co., Ltd., subsidiaries of Shanghai Pharmaceuticals. These changes are not expected to affect the company's controlling shareholder or actual controller.